SCHEMBL1034848

SCHEMBL1034848

c1ccc(Cc2cnc[nH]2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 13/20 1.00
TAAR1 Q96RJ0 3/20 1.00
HRH4 Q9H3N8 4/20 0.71
CYP3A4 P08684 1/20 0.69
MAPT P10636 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.69
CYP2D6 P10635 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9783259 0.85 HRH3 (0.73) HRH3TAAR1HRH4CYP3A4MAPT
SCHEMBL2626857 0.84 HRH3 (1.00) HRH3TAAR1HRH4CYP2D6
SCHEMBL9783245 0.84 HRH3 (0.71) HRH3TAAR1HRH4CYP3A4MAPT
Immethridine SCHEMBL29462340 0.83 HRH3 (1.00) HRH3TAAR1HRH4CYP3A4MAPT
SCHEMBL10217408 0.82 HRH3 (0.69) HRH3TAAR1HRH4CYP3A4MAPT
Immethridine SCHEMBL30053193 0.82 CYP3A4 (1.00) HRH3TAAR1HRH4CYP3A4MAPT
SCHEMBL224745 0.82 TAAR1 (1.00) HRH3TAAR1HRH4
SCHEMBL8009818 0.80 HRH3 (0.67) HRH3TAAR1HRH4CYP3A4MAPT
SCHEMBL28759658 0.80 HRH3 (1.00) HRH3TAAR1HRH4CYP3A4MAPT
SCHEMBL2536900 0.79 HRH3 (0.93) HRH3TAAR1HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108368494-A Methods, compositions and uses of novel FYN kinase inhibitors 沃伦·C·刘 2018-08-03 CN claimed
US-20260103459-A1 SUBSTITUTED AZACYLES AS TRPM8 MODULATORS GIVAUDAN SA (CH) 2026-04-16 US disclosed
EP-4317135-A4 5-BENZYLIMIDAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF WEST CHINA HOSPITAL SICHUAN UNIV (CN) 2025-07-30 EP disclosed
US-20240217936-A1 5-BENZYLIMIDAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF WEST CHINA HOSPITAL, SICHUAN UNIVERSITY (CN) 2024-07-04 US disclosed
US-20240217936-A1 5-BENZYLIMIDAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF WEST CHINA HOSPITAL, SICHUAN UNIVERSITY (CN) 2024-07-04 US disclosed
US-20240217936-A1 5-BENZYLIMIDAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF WEST CHINA HOSPITAL, SICHUAN UNIVERSITY (CN) 2024-07-04 US disclosed
EP-4317135-A1 5-BENZYLIMIDAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF West China Hospital, Sichuan University (CN) 2024-02-07 EP disclosed
EP-4317135-A1 5-BENZYLIMIDAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF West China Hospital, Sichuan University (CN) 2024-02-07 EP disclosed
EP-4317135-A1 5-BENZYLIMIDAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF West China Hospital, Sichuan University (CN) 2024-02-07 EP disclosed
CN-115197148-B 5-benzyl imidazole compound and preparation method and application thereof 四川大学华西医院 2023-12-12 CN disclosed
EP-1981880-B1 USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS HOFFMANN LA ROCHE (CH) 2010-02-24 EP disclosed
WO-2009129094-A2 COMPOSITIONS CONTAINING ANTIVIRAL COMPOUNDS AND METHODS OF USING THE SAME MALLINCKRODT INC. (US) 2009-10-22 WO disclosed
US-20090258843-A1 Compositions Containing Antiviral Compounds and Methods of Using the Same MALLINCKRODT INC. (US) 2009-10-15 US disclosed
US-20070197622-A1 Methods for treating CNS disorders with 4-imidazole derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-08-23 US disclosed
US-20070197622-A1 Methods for treating CNS disorders with 4-imidazole derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-08-23 US disclosed
WO-2007085556-A2 USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2007-08-02 WO disclosed
CN-1181069-C Novel inhibitors of farnesyl-protein transferase ���鹫˾ 2004-12-22 CN disclosed
CN-1346355-A Novel inhibitors of farnesyl-protein transferase SCHERING CORP (US) 2002-04-24 CN disclosed
CN-1284066-A Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors ALLERGEN SALES INC (US) 2001-02-14 CN disclosed
CN-1035113-A The heterogeneous ring compound that is used for the treatment of WELLCOME FOUND (GB) 1989-08-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260103459-A1 SUBSTITUTED AZACYLES AS TRPM8 MODULATORS TRPM8, TRPM7, TRPM5 HRH3 602/4885TAAR1 236/4885HRH4 403/4885
US-20090258843-A1 Compositions Containing Antiviral Compounds and Methods of Using the Same EIF2AK2, MAVS, IRF3 HRH3 2765/4885TAAR1 4398/4885HRH4 2846/4885
US-20070197622-A1 Methods for treating CNS disorders with 4-imidazole derivatives CRY1, GPR119, MTNR1A HRH3 213/4885TAAR1 79/4885HRH4 109/4885
US-20240217936-A1 5-BENZYLIMIDAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF CYP4F11, WASF2, CYP3A5 HRH3 2479/4885TAAR1 4258/4885HRH4 1129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.